The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progressionin metastatic breast cancer (MBC) patients (pts).
Jean-Yves Blay
Research Funding - Cytheris
Olivier Tredan
No relevant relationships to disclose
Christine Menetrier-Caux
Research Funding - Cytheris (B)
Claire Cropet
No relevant relationships to disclose
Thomas Denis Bachelot
No relevant relationships to disclose
Pierre Heudel
No relevant relationships to disclose
Paul E. Rebattu
No relevant relationships to disclose
Gwenaelle Garin
No relevant relationships to disclose
Sylvie Chabaud
No relevant relationships to disclose
Estelle Verronese
No relevant relationships to disclose
Anne Claire Cadore
No relevant relationships to disclose
Valerie Fouillat
No relevant relationships to disclose
Therese Croughs
Employment or Leadership Position - Cytheris
Michel Morre
Employment or Leadership Position - Cytheris
Gilles Clapisson
No relevant relationships to disclose
Christophe Caux
No relevant relationships to disclose
David Pérol
No relevant relationships to disclose
Isabelle Laure Ray-Coquard
Research Funding - Cytheris